278 related articles for article (PubMed ID: 16465545)
1. Population analysis of the pharmacokinetics and the haematological toxicity of the fluorouracil-epirubicin-cyclophosphamide regimen in breast cancer patients.
Sandström M; Lindman H; Nygren P; Johansson M; Bergh J; Karlsson MO
Cancer Chemother Pharmacol; 2006 Aug; 58(2):143-56. PubMed ID: 16465545
[TBL] [Abstract][Full Text] [Related]
2. Model describing the relationship between pharmacokinetics and hematologic toxicity of the epirubicin-docetaxel regimen in breast cancer patients.
Sandström M; Lindman H; Nygren P; Lidbrink E; Bergh J; Karlsson MO
J Clin Oncol; 2005 Jan; 23(3):413-21. PubMed ID: 15585753
[TBL] [Abstract][Full Text] [Related]
3. Lack of relationship between systemic exposure for the component drug of the fluorouracil, epirubicin, and 4-hydroxycyclophosphamide regimen in breast cancer patients.
Sandström M; Freijs A; Larsson R; Nygren P; Fjällskog ML; Bergh J; Karlsson MO
J Clin Oncol; 1996 May; 14(5):1581-8. PubMed ID: 8622075
[TBL] [Abstract][Full Text] [Related]
4. Individually tailored toxicity-based 5-fluorouracil, epirubicin and cyclophosphamide (FEC) therapy of metastatic breast cancer.
Lindman H; Aström G; Ahlgren J; Villman K; Blomqvist C; Nygren P; Bergh J
Acta Oncol; 2007; 46(2):165-71. PubMed ID: 17453364
[TBL] [Abstract][Full Text] [Related]
5. Long-term cardiac follow-up in relapse-free patients after six courses of fluorouracil, epirubicin, and cyclophosphamide, with either 50 or 100 mg of epirubicin, as adjuvant therapy for node-positive breast cancer: French adjuvant study group.
Bonneterre J; Roché H; Kerbrat P; Fumoleau P; Goudier MJ; Fargeot P; Montcuquet P; Clavère P; Barats JC; Monnier A; Veyret C; Datchary J; Van Praagh I; Chapelle-Marcillac I
J Clin Oncol; 2004 Aug; 22(15):3070-9. PubMed ID: 15284257
[TBL] [Abstract][Full Text] [Related]
6. Quality of life in women with breast cancer during the first year after random assignment to adjuvant treatment with marrow-supported high-dose chemotherapy with cyclophosphamide, thiotepa, and carboplatin or tailored therapy with Fluorouracil, epirubicin, and cyclophosphamide: Scandinavian Breast Group Study 9401.
Brandberg Y; Michelson H; Nilsson B; Bolund C; Erikstein B; Hietanen P; Kaasa S; Nilsson J; Wiklund T; Wilking N; Bergh J;
J Clin Oncol; 2003 Oct; 21(19):3659-64. PubMed ID: 14512398
[TBL] [Abstract][Full Text] [Related]
7. [The feasibility of CEF (cyclophosphamide, epirubicin, 5-FU) regimen in the adjuvant setting of primary breast cancer].
Honda S; Toi M; Shimizu S; Hayashi K; Tominaga T
Gan To Kagaku Ryoho; 1997 Apr; 24(6):679-83. PubMed ID: 9126304
[TBL] [Abstract][Full Text] [Related]
8. Limited inter-occasion variability in relation to inter-individual variability in chemotherapy-induced myelosuppression.
Hansson EK; Wallin JE; Lindman H; Sandström M; Karlsson MO; Friberg LE
Cancer Chemother Pharmacol; 2010 Apr; 65(5):839-48. PubMed ID: 19680655
[TBL] [Abstract][Full Text] [Related]
9. [A clinical report of high-dose epirubicin combined with cyclophosphamide and fluorouracil for advanced breast cancer].
Feng J; Zheng X; Dai A
Zhonghua Zhong Liu Za Zhi; 1998 Nov; 20(6):468-70. PubMed ID: 10920949
[TBL] [Abstract][Full Text] [Related]
10. Randomized phase 3 trial of fluorouracil, epirubicin, and cyclophosphamide alone or followed by Paclitaxel for early breast cancer.
Martín M; Rodríguez-Lescure A; Ruiz A; Alba E; Calvo L; Ruiz-Borrego M; Munárriz B; Rodríguez CA; Crespo C; de Alava E; López García-Asenjo JA; Guitián MD; Almenar S; González-Palacios JF; Vera F; Palacios J; Ramos M; Gracia Marco JM; Lluch A; Alvarez I; Seguí MA; Mayordomo JI; Antón A; Baena JM; Plazaola A; Modolell A; Pelegrí A; Mel JR; Aranda E; Adrover E; Alvarez JV; García Puche JL; Sánchez-Rovira P; Gonzalez S; López-Vega JM;
J Natl Cancer Inst; 2008 Jun; 100(11):805-14. PubMed ID: 18505968
[TBL] [Abstract][Full Text] [Related]
11. Acute and late toxicity following adjuvant high-dose chemotherapy for high-risk primary operable breast cancer--a quality assessment study.
Svane IM; Homburg KM; Kamby C; Nielsen DL; Roer O; Sliffsgaard D; Johnsen HE; Hansen SW
Acta Oncol; 2002; 41(7-8):675-83. PubMed ID: 14651213
[TBL] [Abstract][Full Text] [Related]
12. Association of high-dose cyclophosphamide, cisplatin, and carmustine pharmacokinetics with survival, toxicity, and dosing weight in patients with primary breast cancer.
Petros WP; Broadwater G; Berry D; Jones RB; Vredenburgh JJ; Gilbert CJ; Gibbs JP; Colvin OM; Peters WP
Clin Cancer Res; 2002 Mar; 8(3):698-705. PubMed ID: 11895898
[TBL] [Abstract][Full Text] [Related]
13. Inflammatory breast cancer outcome with epirubicin-based induction and maintenance chemotherapy: ten-year results from the French Adjuvant Study Group GETIS 02 Trial.
Veyret C; Levy C; Chollet P; Merrouche Y; Roche H; Kerbrat P; Fumoleau P; Fargeot P; Clavere P; Chevallier B
Cancer; 2006 Dec; 107(11):2535-44. PubMed ID: 17054108
[TBL] [Abstract][Full Text] [Related]
14. Haematological toxicity following different dosing schedules of 5-fluorouracil and epirubicin in rats.
Simonsen LE; Wählby U; Sandström M; Freijs A; Karlsson MO
Anticancer Res; 2000; 20(3A):1519-25. PubMed ID: 10928065
[TBL] [Abstract][Full Text] [Related]
15. Epirubicin-vinorelbine vs FEC100 for node-positive, early breast cancer: French Adjuvant Study Group 09 trial.
Kerbrat P; Roché H; Bonneterre J; Veyret C; Lortholary A; Monnier A; Fumoleau P; Fargeot P; Namer M; Chollet P; Goudier MJ; Audhuy B; Simon H; Montcuquet P; Eymard JC; Walter S; Clavère P; Guastalla JP;
Br J Cancer; 2007 Jun; 96(11):1633-8. PubMed ID: 17505516
[TBL] [Abstract][Full Text] [Related]
16. Population pharmacokinetics of oxaliplatin (85 mg/m2) in combination with 5-fluorouracil in patients with advanced colorectal cancer.
Kho Y; Jansman FG; Prins NH; Neef C; Brouwers JR
Ther Drug Monit; 2006 Apr; 28(2):206-11. PubMed ID: 16628132
[TBL] [Abstract][Full Text] [Related]
17. The effect of busulphan on the pharmacokinetics of cyclophosphamide and its 4-hydroxy metabolite: time interval influence on therapeutic efficacy and therapy-related toxicity.
Hassan M; Ljungman P; Ringdén O; Hassan Z; Oberg G; Nilsson C; Békassy A; Bielenstein M; Abdel-Rehim M; Georén S; Astner L
Bone Marrow Transplant; 2000 May; 25(9):915-24. PubMed ID: 10800057
[TBL] [Abstract][Full Text] [Related]
18. Population pharmacokinetic and limited sampling models for carboplatin administered in high-dose combination regimens with peripheral blood stem cell support.
Shen M; Schilder RJ; Obasaju C; Gallo JM
Cancer Chemother Pharmacol; 2002 Sep; 50(3):243-50. PubMed ID: 12203107
[TBL] [Abstract][Full Text] [Related]
19. Accuracy, feasibility, and clinical impact of prospective Bayesian pharmacokinetically guided dosing of cyclophosphamide, thiotepa, and carboplatin in high-dose chemotherapy.
de Jonge ME; Huitema AD; Tukker AC; van Dam SM; Rodenhuis S; Beijnen JH
Clin Cancer Res; 2005 Jan; 11(1):273-83. PubMed ID: 15671556
[TBL] [Abstract][Full Text] [Related]
20. [A case of metastatic breast cancer successfully treated with weekly low-dose epirubicin (EPI), cyclophosphamide (CPA), 5-fluorouracil (5-FU) and medroxyprogesterone (MPA)].
Satoh Y; Une Y; Fujisawa J; Uchino J
Gan To Kagaku Ryoho; 1994 Oct; 21(14):2509-12. PubMed ID: 7944500
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
